Background: A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients. Methods: Patients (n = 307, with 137 events after a median follow-up of 13.6 years) from  ve European centers were divided into high-and low-risk groups based on the gene signature classi cation and on clinical risk classi cations. Patients were assigned to the gene signature low-risk group if their 5-year distant metastasis -free survival probability as estimated by the gene signature was greater than 90%. Patients were assigned to the clinicopathologic low-risk group if their 10-year survival probability, as estimated by Adjuvant! software, was greater than 88% (for estrogen receptor [ER] -positive patients) or 92% (for ERnegative patients). Hazard ratios (HRs) were estimated to compare time to distant metastases, disease-free survival, and overall survival in high-versus low-risk groups. ( ( Gicroarray( technology( is( revolutioniKing( our( understanding( of(cancer(biology(through(the(simultaneous(study(of(the(eMpresN sion(of(tens(of(thousands(of(genes,(or(even(of(the(entire(human( genome.(Oifferential(gene(eMpression(or(molecular(pro(ling(has( ( ( Af liations of authors:( ( International( Orug( Oevelopment( Institute,( Prussels,( Pelgium(QGP,(GA,(RPTU(Institut(!ules(Pordet,(Prussels,(Pelgium(Q:D,(C:,(RC,(Amsterdam,( EBTU( ( European( Institute( of( Vncology( and( Wniversity( of( Gilan( :chool( of( Gedicine,( Gilan,( :wiss( Institute( of( EMperimental( Cancer( Besearch,( Epalinges( Z( the( :wiss( Institute( of( Pioinformatics,( Dausanne,( :witKerland( QGOTU(Agendia( P.4.( ( Amsterdam,(AGG,(ARTU(Institut(Gustave(Boussy,(4ille[uif ( Pordet,( 8?8( ( Poulevard(de(Waterloo,(8@@@(Prussels,(which(permits(unrestricted(nonNcommercial(use,(distribuN tion,(and(reproduction(in(any(medium,(provided potential(to(substantially(re(ne(cancer(prognosis,(basal(and(luminal,(have(been(identi(ed(by(gene(eMpression( pro(ling( of( breast( cancer,( each( with( the( potential( to( be( subdiN vided( into( two( or( three( subtypes.( In( addition,( these( molecular( portraits(seem(to(be(remarkably(stable(as(tumors(progress(from( primary(to(metastatic(disease(( ( 8 ) ( .( ( In( one( of( the( microarray( studies( ( ( 5 )( ,IT(studied(a(narN rowly ( de(ned( subset( of( breast( cancer( patients,( i.e.,( those( aged( hh(years( or( younger( who( were( diagnosed( with( tumors( smaller( than(h(cm(QT8aT?T,(and(were(treated(only(with(local( i( regional(therapies.(The( eM( pression(of(?F8(genes(was(found(to(be(statistically(signi(cantly( associated( with( disease( outcome,( as( de(ned( by( the( presence( of( distant( metastasis( within( h( years.( This( group( of( genes( was( ( reduced( subsejuently( to( a( core( set( of( 9@( genes( that( together( 887k( ABTICDE:( 
 10 ) ( .( The( 9@Ngene( signature( correctly( identi(ed(not(only(the(patients(who(needed(ad[uvant(( chemotherapy( but(also(those(who(did(not(need(ad[uvant(chemotherapy, (leading( to( a( ?@l( i( F@l( reduction( in( the( number( of( women( who( would( otherwise(receive(chemotherapy(without(compromising(longNterm( clinical( outcome.( The( 9@Ngene( signature( was( then( applied( to( a( larger(test(set(of(?6h(breast(cancer(patients(from(the(same(instituN tion, (and(the(results(con(rmed(that(the(signature(could(clearly(disN tinguish(patients(according(to(their(8@Nyear(survival(outcome(( ( 6 ) ( .( ( :ince( the( publication( of( these( results,( a( number( of( authors( have(highlighted(critical(issues(in(the(use(of(microarray(data(for( prognostic( classi(cation,( including( gene( selection( bias,( error( ( estimation,(fragility(of(gene(signatures,(and(overoptimistic(perN formance(estimation(due(to(model(over(t(( ( 11 -13 ) ( .(Goreover, (as( promising(as(gene(signatures(are, (it(still(needs(to(be(proven(that( they(provide(additional(information(to(the(clinicopathologic(risk( criteria(that(are(currently(used(in(the(clinic.(:ome(authors(have( eMpressed(doubts(that(they(will(add(further(prognostic(value(to( that( provided( by( the( best( risk( classi(cations( based( on( factors( such( as( age, ( tumor( siKe, ( tumor( grade, ( nodal( involvement, ( and( presence(of(hormonal(receptors(( ( 9 , 10 , (14) (15) (16) (17) ( .( ( If(the(clinical(utility(of(gene(signatures(can(be(established( m( that( is, ( if( they( prove( to( reliably( identify( patients( in( whom( ad[uvant( chemotherapy(is(de(nitely(not(indicated(despite(having(poor(clin( N ical( risk( factors( and( patients( who( need( chemotherapy( despite( ( having(good(clinical(risk(factors( m( they(will(have(enormous(potenN tial(for(better(individualiKation(of(treatment(options(in(breast(canN cer(therapy(( ( 18 ) ( .(This(potential( m( and(the(use(of(gene(signatures(in( prognostication( m( rejuires(that(the(recently(proposed(gene(signatures( be( validated( independently, ( preferably( by( teams( eMternal( to( the( original( institutions, ( using( prospectively( de(ned( criteria.( In( this( paper, 
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Patients
. U( and( !ohn( Badcliffe(`ospital,( VMford,( W.] . ( Patients( were( eligible( for( inclusion( if( they( were( younger( than(>8(years(old(at(diagnosis, (diagnosed(before(8666(with(nodeN negative, ( T8( i( T?( Q( !( h( cmT( breast( cancer, I(to(validate(the(9@Ngene (signature,(hereafter(referred(to(as( the(( e( original( f( (series(( ( 6 ) ( .(The(validation(protocol(was((naliKed(in( !uly(?@@k.(All(institutional(ethics(committees(approved(the(use(of( the(tumor(material(for(the(purposes(described(in(this(article,(and( patients(provided(written(informed(consent. ( Initially,(froKen(samples(from(eligible(patients(Qn(n(k@FT(were( sent(from(all(clinical(centers(to(-] I(for (as(pre( ( viously(described(( ( 5 ) (leaving(F?>(samples(available(for(analysis.(Paraf(nN embedded(tumor(samples(from(all(patients(in(both(the(original(and( the( validation( series( were( sent( to( the( Oepartment( of( Pathology( at( the( European( Institute( of( Vncology, ( Gilan, ( where( the( same( pathologist(QG4T(determined(estrogen(receptor(QEBT(status(( ousing( immunohistochemistry(( ( 19 ) ( p(and(histologic(grade(ousing(the(Elston( and(Ellis(method(( ( 20 ) ( p.(Whenever(possible, (these(central(patholN ogy(data(were(used(to(determine(EB(status(Qn(n(?87T(and(histologic( grade(Qn(n(?F9TU(otherwise(the(local(pathology(data(obtained(at(the( original(clinical(center(were(used.(Clinical(centers(were(visited(by( two(independent(auditors(who(carried(out(source(data(veri(cation( of(all(data(in(the(validation(series.(Clinical, (pathologic, (Prussels, (Pelgium. ( Gicroarray(analysis(was(performed(at(Agendia(Daboratories, (the(cut(point(used(in(the(original(study( ( ( 5 ) ( .(The(previously(established(classi(er(de(ned(good(prognosis( as(a(probability(of(hNyear(distant(metastasis( i( free(survival(of(more( than(6@l(( ( 5 ) ( .(The(gene(signature(risk(classi(cation(was(given(as( a( dichotomiKed( value( onlyc( high( or( low( risk.( Baw( microarray( data(and(clinical(information(are(available(at(the(European(Pio( N in( formatics( Institute( ArrayEMpress( database( Q( httpcaawww.ebi.ac. ukaarrayeMpressa( T, (where(a(study(statistician(QGOT(reviewed(and(indepenN dently( applied( Agendia's( proprietary( analysis( program( to( the( normaliKed(microarray(raw(data(to(reproduce(the(risk(classi(caN tion.(The(risk(classi(cation(agreement(between(:wiss(Institute(of( Pioinformatics(and(Agendia(was(assessed(by(independent(study( statisticians(QGP, (GA, (RPT.(The(concordance(between(the(risk( classi(cation( produced( by(Agendia( and( the( eMternal( team( was( 8@@l(as(veri(ed(by(the(independent(statisticians. ( The(aim(of(this(validation(study(was(to(eMamine(whether(the( 9@Ngene(signature(had(prognostic(value(independent(of(the(best( clinical(risk(classi(cations.(The(prognostic(value(of(the(gene(sigN nature(was((rst(assessed(with(respect(to(the(:t(Gallen(criteria(( ( 9 ) (were(classi(ed(as(low(risk.(`owever, (the(:t(Gallen(criteria( classi(ed(very(few(patients(as(low(risk, ( therefore, ( also( asN sessed(using(the(recently(introduced(Ad[uvantq(software(o( httpcaa www.ad[uvantonline.com( ( ( ( 16 ) ( p, ( which( calculates( 8@Nyear( surN vival(probability(based(on(the(patient's(age, (tumor(siKe(and(grade, ( tumor( EB( status, ( and( nodal( status( Qwhich( was( negative( for( all( patients(in(this(studyT.(In(a(recent(eMternal(validation, (Ad[uvantq( software(was(shown(to(accurately(predict(overall(survival, (breast( cancer( i( speci(c(survival, (and(eventNfree(survival(in(k@7F(women( diagnosed(with(early(breast(cancer(in(Pritish(Columbia(between( 8676(and(866F(( ( 21 ) ( .( ( Although(it(is(possible(to(use(the(outcomes(produced(by(Ad[uN vantq(software(as(a(continuous(variable, (version(9.@T(of(at(least(77l(if(8@l(or(more(of(the(tumor( cells(eMpressed(detectable(EB(Qi.e., (EBNpositive(tumorsT(and(of( at(least(6?l(if(EB(eMpression(was(seen(in(less(than(8@l(of(the( tumor( cells( Qi.e., ( EBNnegative( tumorsT.(These( two( cutoffs( were( chosen(to(re(ect(the(fact(that(patients(with(EBNpositive(tumors( routinely(receive(ad[uvant(endocrine(therapy(owith(an(estimated( absolute( 8@Nyear( survival( bene(t( of( approMimately( kl( overall( ( ( 22 ) ( p, ( although( none( of( the( patients( in( the( validation( series( reN ceived(ad[uvant(endocrine(therapy, (regardless(of(their(EB(status.( owever, (to(rule(out(the(possibility(that(our(results(were(depenN dent(on(the(choice(of(clinical(cutoff, (we(carried(out(a(sensitivity( analysis(in(which(we(varied(the(8@Nyear(overall(survival(probaN bility(cutoff(that(de(ned(low(risk, (as(predicted(by(Ad[uvantq(softN ware, (from(>@l(Qin(which(case(most(patients(were(classi(ed(in( the(low( i( clinical(risk(groupT(to(6hl(Qin(which(case(most(patients( were(classi(ed(in(the(high( i( clinical(risk(groupT, (without(distincN tion(between(EBNpositive(and(Nnegative(patients.( ( Endpoints ( We(analyKed(three(main(endpointsc(time(from(surgery(to(disN tant(metastases, (which(was(the(endpoint(used(to(identify(the(gene( signature( ( ( 5 ) ( ( Qall( other( events( were( ignored( for( this( endpointTU( overall(survival, (which(was(de(ned(as(time(from(surgery(to(death( from(any(causeU(and(diseaseNfree(survival, (which(was(de(ned(as( time(from(surgery(to(any(recurrence(Qlocal(or(regionalT, (second( breast(primary, (distant(metastasis, (or(death(from(any(cause.(The( ]aplan( i( Geier(productNlimit(estimator(was(used(to(display(timeN toNevent(curves(for(these(three(endpoints.( ( Validation Strategy ( 4alidation(of(the(gene(signature(was(based(on(the(estimation( of(haKard(ratios, (which(were(used(to(juantify(the(relative(risk(of( an(event(in(the(highNrisk(group(compared(with(the(lowNrisk(group.( A(haKard(ratio(above(8.@(indicates(that(patients(in(the(highNrisk( group(have(a(higher(probability(of(an(event(Qdistant(metastasis, ( death(from(any(cause, (or(recurrence(or(deathT(than(patients(in(the( lowNrisk( group( for( the( outcomes( considered( Qtime( to( distant( ( metastasis, ( overall( survival, ( and( diseaseNfree( survival, ( respecN tivelyT.(`aKard(ratios(were(strati(ed(by(clinical(center(to(account( for(( possible(heterogeneity(in(patient(selection(or(other(potential( ( confounders(among(the(various(centers.(`aKard(ratios(for(the(risk( groups(de(ned(by(the(gene(signature(were(estimated(with(stratiN (cation( for( clinical( risk( to( re(ect( the( prognostic( impact( of( the( gene(signature(over(and(above(that(of(clinicopathologic(factors( Qad[usted(haKard(ratiosT.( ( The(ad[usted(haKard(ratios(Qwith(their(6hl(con(dence(interN vals(oCIspT(for(the((ve(institutions(that(supplied(patients(for(this( study(were(displayed(on(forest(plots(and(tested(for(heterogeneity( using(a(chiNsjuare(test(with(four(degrees(of(freedom.(The(impact( of( the( duration( of( followNup( on( the( ad[usted( haKard( ratios( was( analyKed(by(censoring(all(observations(at(increasing(time(points.( ( We(estimated(that(approMimately(8@@(patients(with(a(cancerN related(event(would(be(needed(for(the(validation(to(yield(results( with(both(clinical(relevance(Qi.e., (doubling(of(the(risk(of(an(eventT( and(statistical(signi(cance(Qi.e., (a(power(of(6@l(to(detect(a(haKN ard(ratio(of(?.@(or(greater(at(a(statistical(signi(cance(level(of(.@hT.( After(a(median(followNup(of(8F.>(years, (a(total(of(8F9(patients(in( the(validation(series(had(at(least(one(event.(These(events(included( >7(recurrences, (F8(second(primary(cancers, (99(distant(metastaN ses, (and(7?(deaths. ( ( Sensitivity and Speci city ( :ensitivity(and(speci(city(were(estimated(for(both(risk(assessN ments(Qi.e., (the(gene(signature(and(clinicopathologic(assessmentsT( for(distant(metastases(within(h(years(Qthe(endpoint(used(to(derive( the(gene(signatureT(and(for(death(within(8@(years(Qthe(endpoint( used(to(de(ne(the(clinical(cutoff(when(using(Ad[uvantq(softwareT.( :ensitivity(was(de(ned(as(the(probability(that(a(patient(who(eMpeN rienced(the(event(of(interest(was(in(the(highNrisk(group(and(speciN (city(as(the(probability(that(a(patient(who(did(not(eMperience(the( event(of(interest(was(in(the(lowNrisk(group.(TimeNdependent(reN ceiver(operating(characteristic(QBVCT(curves(( ( 23 ) ( (were(computed( by(using(the(tumor(eMpression(level(for(the(gene(signature(( ( 5 ) ( (and( the(8@Nyear(survival(probability(for(the(Ad[uvantq(software(( ( 17 ) ( Oata(on(tumor(siKe(were(missing(for(three(of(the(F?>(patients( in(the(validation(series, (and(8>(patients(were(found(to(be(ineligible( in(the(independent(data(veri(cation(Qfor(8@(patients, (only(comedoN carcinoma( or( ductal( carcinoma( in( situ( was( detected( at( central( ( pathology(reviewU(two(patients(had(metastatic(disease(at(the(time( of(diagnosisU(one(patient(had(a(bilateral(breast(cancerU(one(patient( had(a(previous(malignancyU(one(patient(was(older(than(>8(yearsU( and(one(patient(had(a(tumor(that(was(larger(than(h(cmT.(Vf(the( remaining(F@9(patients, (data(on(EB(status(were(missing(for((ve( patients.(All(analyses(were(repeated(with(the(inclusion(of(the(inN eligible(patients, (and(the(results(were(similar(Qdata(not(shownT.( ( Patient Characteristics ( The( 9@Ngene( signature( risk( classi(cation( was( assessed( for( each(tumor, (and(tumors(were(scored(as(low(or(high(risk(according( to( the( previously( established( classi(er( ( ( 5 ) whom(clinical(risk(could(be(calculated(using(the(Ad[uvantq(softN ware(Qi.e., (the(patients(for(whom(data(on(EB(status(were(availN ableT.( The( patients( were( divided( into( four( groups( according( to( their( clinical( and( gene( signature( risks.(Analysis( of( 8@Nyear( surN vival(data(Q( Table(8( T(showed(that, (for(patients(in(the(gene(signature( highNrisk( category, ( the( 8@Nyear( overall( survival( was( @.>6( for( ( patients(in(both(low( i( (and(high( i( clinical(risk(groups, (whereas(for( patients( in( the( gene( signature( lowNrisk( category, ( the( 8@Nyear( ( survivals( were( @.77( and( @.76, ( respectively.( The( ]aplan( i( Geier( estimates(of(time(to(distant(metastases, (overall(survival, (and(diseaseN free(survival(for(the(four(groups(of(patients(Q( Rig.(8( T(suggest(that, ( for( groups( with( discordant( risk( assessments( Qi.e., ( high( risk( acN cording(to(one(risk(classi(er(and(low(risk(according(to(the(otherT, ( the(gene(signature(provided(stronger(prognostic(information(than( the(clinicopathologic(criteria.( ( ( ( ( ( ( ( ( ( ( The(unad[usted(haKard(ratios(for(the(three(outcomes(in(highN( versus(lowNrisk(patients(as(de(ned(by(traditional(individual(cliniN copathologic(factors(and(by(various(risk(classi(cations(are(shown( in(( Table(?( .(The(prognostic(value(of(the(gene(signature(was(stronN ger(than(that(of(the(individual(traditional(risk(factors(and(of(the( commonly(used(clinicopathologic(risk(classi(cations.(The(unadN [usted( gene( signature( haKard( ratio( for( time( to( distant( metastases( was(?.F?(Q6hl(CI(n(8.Fh(to(k.@@T, (higher(than(that(for(any(of(the( other(risk(factors(or(classi(cations.(Ad[ustment(of(the(gene(signaN ture( haKard( ratio( for( the( :t( Gallen( criteria, ( and( for( the( clinical( risk( groups( based( on( 8@Nyear( survival( probability( as( calculated( by( Ad[uvantq( software( resulted( in( gene( signature( ( haKard(ratios(of(?.8h(Q6hl(CI(n(8.?h(to(F.98T, (?.8h(Q6hl(CI(n( 8.86( to( F.6?T, ( and( ?.8F( Q6hl( CI( n( 8.86( to( F.7?T, ( respectively.( The( gene( signature( haKard( ratio( for( overall( survival( was( ?.96( Q6hl(CI(n(8.>@(to(k.79T(without(ad[ustment(and(?.>6(Q6hl(CI(n( 8.hF(to(k.9FT, (?.76(Q6hl(CI(n(8.h7(to(h.?6T, (and(?.>F(Q6hl(CI(n( 8.kh(to(k.96T(with(the(respective(ad[ustments.(The(gene(signature( haKard(ratio(for(diseaseNfree(survival(was(8.h@(Q6hl(CI(n(8.@k( to(?.8>T(without(ad[ustment(and(8.k8(Q6hl(CI(n(@.69(to(?.@>T, ( 8.kh(Q6hl(CI(n(@.69(to(?.8>T, (and(8.F>(Q6hl(CI(n(@.68(to(?.@FT( with(the(respective(ad[ustments.( ( ( ( ( ( The(reverse(analysis(was(also(performed, (i.e., (the(haKard(raN tios(for(the(clinical(risk(classi(cations(were(ad[usted(for(the(gene( signature.(Ror(the(risk(classi(cation(according(to(the(Ad[uvantq( software, (the(unad[usted(haKard(ratio(for(time(to(distant(metasN tases(was(8.>7(Q6hl(CI(n(@.6?(to(F.@9T(without(ad[ustment(and( 8.?>(Q6hl(CI(n(@.>>(to(?.k@T(when(ad[usted(for(the(gene(signaN tureU(for(overall(survival, (the(haKard(ratios(were(8.>9(Q6hl(CI(n( @.6F( to( ?.67T( without( ad[ustment( and( 8.@7( Q6hl( CI( n( @.h6( to( 8.66T(with(ad[ustmentU(and(for(diseaseNfree(survival, (the(haKard( ratios(were(8.F@(Q6hl(CI(n(@.7>(to(8.6hT(without(ad[ustment(and( 8.@F(Q6hl(CI(n(@.>9(to(8.h6T(with(ad[ustment. ( ( ( Rorest( plots( of( the( gene( signature( haKard( ratios( for( each( ( center,( ad[usted( for( the( clinical( risk( groups( as( de(ned( by( the( Ad[uvantq( software( Q( Rig.( ?,(A( i( C( T,( indicated( that( there( was( no( statistically( signi(cant( heterogeneity( among( the( (ve( centers( from(which(the(validation(series(was(drawn(for(any(of(the(endN points( considered.(`owever,( statistically( signi(cant( heterogeN neity(was(apparent(between(the(validation(series(and(the(original( series,( with( the( latter( series( showing( much( larger( haKard( ratios( for( all( endpoints( considered.( Py( contrast,( forest( plots( of( the( Ad[uvantq(software(clinical(risk(( haKard(ratios( ,(ad[usted(for(the( gene( signature( Q( Rig.( ?,( O( i( R( T,( revealed( no( statistically( signi(N cant(heterogeneity(among(the(different(centers(of(the(validation( series( or( between( the( validation( series( and( the( original( series( for(any(of(the(endpoints.( ( ( ( ( ( Impact of Clinical Risk Cutoff ( In(a(sensitivity(analysis,(we(varied(the(cutoffs(that(de(ned(low( risk(in(the(Ad[uvantq(software(and(used(the(resulting(clinical(risk( groups( to( ad[ust( the( gene( signature( haKard( ratios( Q( Rig.( F( T. ( ( ( ( ( ( ( Characteristics(of(patients(in(the(validation(series(according(to(their(clinical(and(gene(signature(risks( r( ( ( ( ( Clinical(low(risk ( ( Clinical(high(risk Characteristic Gene(signature( low(risk(Qn(n(h?T Gene(signature( high(risk(Qn(n(?7T Gene(signature( low(risk(Qn(n(h6T Gene(signature( high(risk(Qn(n ( r( ( Although( the( validation( series( included( F@9( patients, ( those( whose( clinical( risk( could( not( be( calculated( due( to( missing( values( for( any( of( the( variables( were( eMcluded(Qn(n(hT.( ( Q( P( (values(not(shownT, (regardless(of(the(cutoff(chosen, (for(both( time( to( distant( metastases( and( overall( survival.(`owever, ( for( ( diseaseNfree(survival(most, (but(not(all, (cutoffs(achieved(only(borN derline(statistical(signi(cance.( ( ( ( ( ( ( The( analyses( reported( above( were( carried( out( without( arbiN trary( censoring( of( observations.(`owever, ( because( the( median( followNup(time(in(the(original(series(was(less(than(half(that(of(the( validation(series(Q>.9(years(versus(8F.>(years, (respectivelyT, (we( also(calculated(the(gene(signature(haKard(ratios(ad[usted(for(clinN ical(risk(groups(as(de(ned(by(Ad[uvantq(software(with(arbitrary( censoring(of(all(observations(at(increasing(time(points.(As(shown( in(( Rig.(k( , (the(ad[usted(gene(signature(had(the(greatest(prognostic( value( Qas( shown( by( the( highest( haKard( ratioT( at( identifying( paN tients(at(high(risk(of(an(event(within(h(years.(These(analyses(sugN gest(that(the(different(duration(of(followNup(may(eMplain(some(of( the( discrepancy( in( haKard( ratios( reported( between( the( original( series(and(the(current(validation(series.( ( ( ( ( ( Sensitivity and Speci city ( TimeNdependent(BVC(curves(Q( Rig.(h( T(showed(that(the(predicN tive(accuracy(of(the(gene(signature(was(as(least(as(good(as(that(of( Ad[uvantq(software, (with(a(high(sensitivity(Qi.e., (a(low(probability( of(falsely(classifying(a(patient(as(low(riskT.(The(sensitivities(for( distant(metastases(within(h(years(and(for(death(within(8@(years( were(similar(for(the(gene(signature(and( [uN vantq(software(was(slightly(higher(than(that(of(the(gene(signature( and(the(speci(city(was(slightly(lower.(In(contrast, (among(the(79( patients(with(a(discordant(gene(signature(and(Ad[uvantq(risk(clasN si(cation, (the(sensitivity(of(the(Ad[uvantq(software(was(very(poor, ( as(was(also(suggested(by(the(] ( Vur(analyses(con(rm(that(the(9@Ngene(signature(( ( 5 ) ( (is(a(strong( prognostic(factor(for(time(to(distant(metastases(and(overall(surN vival(in(untreated(patients(with(nodeNnegative(breast(cancer, (with( unad[usted(haKard(ratios(of(?.F?(Q6hl(CI(n(8.Fh(to(k.@@T(and(?.96( Q6hl( CI( n( 8.>@( to( k.79T, ( respectively.(The( signature( remained( a( statistically( signi(cant( prognostic( factor( for( time( to( distant( metastases( and( survival( even( after( ad[ustment( for( various( risk( classi(cations( that( take( into( account( all( clinicopathologic( facN tors(known(to(have(prognostic(value(in(this(disease.(In(particular, ( when(ad[usted(for(the(clinical(risk(groups(based(on(8@Nyear(surN vival( probability( as( calculated( by( the( Ad[uvantq( software, ( the( gene(signature(haKard(ratios(were(?.8F(Q6hl(CI(n(8.86(to(F.7?T( for(time(to(distant(metastases, (?.>F(Q6hl(CI(n(8.kh(to(k.96T(for( overall(survival, (and(8.F>(Q6hl(CI(n(@.68(to(?.@FT(for(diseaseN free( survival( Q( Rig.( ?( T.( QThe( lack( of( statistical( signi(cance( for( ( diseaseNfree(survival(is(not(surprising(because(the(signature(was( developed(using(only(time(to(distant(metastases(as(an(endpoint.T( These(results(indicate(that(the(gene(signature(adds(independent( prognostic( information( to( that( provided( by( a( risk( Table 2 . (the(event(considered(was(death(from(any(cause.(`aKard(ratios(above(8.@(indicate(a(worse(outcome.( ( ( ( ( t( ( ( ( Ror(diseaseNfree(survival, (the(event(considered(was(death(or(recurrence.(`aKard(ratios(above(8.@(indicate(a(worse(outcome .( ( v( ( 15 ) ( .( ( ( ( w( ( ( ( ( 9 ) . ( ( ( ( ( xx( ( ( ( 5 ) .( ( ( ( ( Fig. 2 . (ad[usted(for(the(gene(signature(risk.(Q( A( (and(( D( T(Time(to( distant( (]I, (CB`, (G`, (and(!B`T(combined. ( ( Size of squares ( (is(inversely(proportional(to(the(variance(of(the(haKard(ratio( Interestingly, (when(the(reverse(analysis(was(performed, (i.e., ( when(clinical(risk(haKard(ratios(were(ad[usted(for(the(gene(sigN nature, (none(of(the(clinical(risk(classi(cations(retained(statistical( signi(cance(Q( Rig.(?( T.(This((nding(suggests(that(most(of(the(inN formation( provided( by( risk( groups( based( on( clinicopathologic( ( factors( is( subsumed( by( the( gene( signature.( The( ]aplan( i( Geier( curves(Q( Rig.(8( T(provide(additional(evidence(for(this(conclusion(in( that( within( each( gene( signature( risk( group( the( curves( for( low( i( ( versus( high( i( clinical( risk( groups( were( close( to( each( other.( Ror( patients(in(the(gene(signature(highNrisk(group, (the(point(estimate( of(8@Nyear(survival(was(@.>6(in(both(the(low( i( (and(high( i( clinical( risk(groups, (and(for(patients(in(the(gene(signature(lowNrisk(group, ( the(point(estimates(of(8@Nyear(survival(were(@.77(and(@.76, (reN spectively(Q( Table(8( T, (thus(demonstrating(the(higher(discriminaN tory(prognostic(ability(of(the(gene(signature.( ( We(also(found(that(the(prognostic(value(of(the(gene(signature( was(almost(completely(independent(of(the(de(nition(of(clinical( risk.(That(is, (a(series(of(ad[ustments(for(clinical(risk(using(varyN ing(cutoff(points(in(the(Ad[uvantq(software(produced(only(minor( changes(in(the(gene(signature(haKard(ratios(Q( Rig.(F( T.(The(approach( used( in( our( analyses( m( i.e., ( estimating( ad[usted( haKard( ratios( through( strati(cation( m( is( preferable( to( a( multivariable( analysis( because(it(does(not(rejuire(any(assumption(of(proportional(haKN ards(for(either(the(gene(signature(or(the(clinicopathologic(factors.( Goreover, (it(is(less(sensitive(to(random((uctuations(in(the(data( ( ( Fig. 3.( ( (( (aKard(ratios(Qand(6hl(con(dence(intervalsT(for(gene(signature(highNrisk( versus( lowNrisk( groups, ( ad[usted( for( the( clinical( risk( groups( based( on( 8@Nyear( survival( probability( as( calculated( by(Ad[uvantq( software.( The( MNaMis( indicates( the(cutoff(points(of(the(8@Nyear(survival(probabilities(used(to(de(ne(high(clinical( risk( in( the( ad[ustment.( ( A( T(Time( to( distant( metastasesU( ( B( T( overall( survivalU( and( ( C( T(diseaseNfree(survival.(( Diamonds( , (haKard(ratiosU(( vertical lines( , (6hl(con(dence( intervalsU(( shaded bars( , (proportion(of(patients(in(each(high( i( clinical(risk(group(as( de(ned(by(each(cutoff(for(8@Nyear(survival.( ( ( ( High clinical risk defined as probability of 10-year survival lower than 0.1 1 10 ( ( Fig. 4 . ( ( ( ( (aKard( ratios( Qand( 6hl( con(dence( intervalsT( for( gene( signature( highN risk( versus( lowNrisk( groups, ( ad[usted( for( clinical( risk( groups( based( on( 8@Nyear( survival(probability(as(calculated(by(Ad[uvantq(software, (for(increasing(arbitrary( censoring( times.( The( MNaMis( indicates( the( time( at( which( all( observations( were( censored.( ( A( T( Time( to( distant( metastasesU( ( B( T( overall( survivalU( and( ( C( T( diseaseN free(survival.(( Diamonds( , (haKard(ratiosU(( vertical lines( , (6hl(con(dence(intervalsU( ( shaded bars( , (proportion(of(patients(in(each(time(point.(It(should(be(noted(that( when( the( data( were( censored( at( ?( years, ( all( eight( events( were( in( the( highNrisk( group(and(no(haKard(ratio(could(be(estimated.( and ( multicolinearity( between( the( variables, ( which( may( lead( to( model(instability(in(multivariable(analysis(( ( 24 )( .( ( There( was( no( evidence( of( heterogeneity( among( the( various( centers(participating(in(the(validation(study(for(any(of(the(endpoints( Q( Rig.(?( T.(In(contrast, (there(was(striking(evidence(of(heterogeneity( between( the( validation( and( the( original( series( ( ( 6 )( c( the( haKard( ( ratios( in( the( original( series( were( much( higher( than( those( in( the( validation( series( for( risk( classi(cations( based( on( either( the( clinicopathologic(factors(or(the(gene(signature.(The(gene(( signature( haKard(ratio(also(remained(much(higher(after(ad[ustment(in(the( original(series(( ( 6 ) ( (than(in(the(current(validation(series.(It(has(preN viously(been(noted(( ( 12 ) ( (that(the(inclusion(in(the(original(series(of( patients(whose(data(were(used(in(the(development(of(the(9@Ngene( signature(may(have(in(ated(the(discriminatory(power(of(the(sigN nature( in( that( study, ( even( though( analytic( measures( had( been( ( ( Fig. 5.( ( (( ( Beceiver(operating(characteristic(QBVCT(curves(of(gene(signature(and(of( Ad[uvantq(software.(Q( top( T(BVC(curves(for(metastases(within(h(years(Q( left( T(and( for( death( within( 8@( years( Q( right( T( for( gene( signature, ( using( the(Agendia( score( Qcorrelation( of( the( gene( signature( with( the( previously( established( classi(erT.( Q( bottom( T(BVC(curves(for(metastases(within(h(years(Q( left( T(and(for(death(within( 8@( years( Q( right( T( for( Ad[uvantq( software, ( using( the( score( generated( by( the( Ad[uvantq(online(software.(AWC(n(area(under(the(curve.( ( ( ( Adjuvant! score, for overall survival at 10 years ( ( Table 3 . Ad (and(siM(for(the(:t(Gallen(criteria.( ( ( ( ( ( tClinical(high(risk, (gene(signature(low(risk. ( ( v( ( Clinical(low(risk, (gene(signature(high(risk.( ( taken(to(limit(this(effect(( ( 12 )( .(It(should(also(be(noted(that(the(only( clinical(factor(that(reached(statistical(signi(cance(in(the(validaN tion( series( was( EB( status, ( which( suggests( that( the( selection( of( patients(who(had(not(received(systemic(ad[uvant(treatment(in(the( validation( series( may( have( yielded( a( sample( of( nodeNnegative( breast(cancer(patients(with(a(relatively(better(outcome(than(what( would(be(eMpected(in(a(populationNbased(series.(All(clinical(data( were(carefully(reviewed(by(independent(site(audits, (so(it(is(unN likely(that(the(juality(of(these(data(could(have(affected(our(results( to(an(eMtent(suf(cient(to(eMplain(the(differences(between(the(reN sults(of(the(validation(and(original(series.(Dikewise, (it(seems(unN likely(that(a(problem(with(the(juality(of(the(pathologic(data(in(the( validation(series(could(eMplain(the(differences(with(the(original( series.( When( the( analysis( was( restricted( to( patients( for( whom( both( centrally( and( locally( reviewed( pathology( data( were( availN able, (the(results(were(almost(identical(regardless(of(whether(the( central( or( local( pathology( data( were( used( Qdata( not( shownT.(A( plausible(eMplanation(for(the(observed(discrepancy(between(the( validation( series( and( the( original( series( is( the( difference( in( followNup(time(o8F.>(years(for(the(validation(series(and(>.9(years( for(the(original(series(( ( 6 )( p.(As(( Rig.(k( (shows, (the(behavior(of(the( ad[usted( haKard( ratio( of( the( gene( signature( shows( substantial( variation(over(time, (suggesting(that(the(ability(of(the(gene(signaN ture(to(identify(those(who(will(develop(distant(relapse(is(greatest( within(h(years(of(diagnosis.( ( The(differences(in(the(results(from(the(original(and(validation( series, (whatever(their(cause, (underline(the(need(to(validate(gene( signatures( on( independent( datasets( from( patients( with( suf(N ciently(long(followNup(before(they(can(be(used(routinely(in(the( clinic( for( prognostic( or( predictive( purposes.( The( very( long( ( followNup(of(patients(in(our(validation(series(enabled(us(to(demN onstrate( that( the( risk( classi(cation( by( gene( signature( provides( additional(independent(prognostic(information(from(that(of(clinN icopathologic(features(Q( Rig.(F( T(but(is(highly(dependent(on(cenN soring( time( Q( Rig.(k( T.( We( also( achieved( our( main( ob[ectives( of( the(validation(study, (i.e., (to(determine(whether(the(9@Ngene(sigN nature(had(reproducible(prognostic(value(across(different(patient( populations, ( different( laboratories, ( and( different( biostatistical( facilities.( ( Although(our(results(demonstrated(that(ad[usted(haKard(ratios( are(a(clinically(useful(measure(to(juantify(the(impact(of(the(gene( signature( over( and( above( that( of( clinicopathologic( factors, (which(aims(to(spare(8@l( i( 8hl(of(women(with(nodeN negative(earlyNstage(breast(cancer(ad[uvant(chemotherapy(without(compromising( longNterm(disease(outcome.(BandomiKation(will(be(between(gene(signature(and( Ad[uvantq(for(ad[uvant(chemotherapy(prescription(for(those(cases(discordant(for( risk(classi(cation(by(the(two( 
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